Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 1Recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Carcinoma, Non-Small-Cell Lung 15Breast Neoplasms 14Sarcoma 11Squamous Cell Carcinoma of Head and Neck 10Glioblastoma 10Esophageal Neoplasms 9Rectal Neoplasms 8Stomach Neoplasms 7Urinary Bladder Neoplasms 6Neoplasms 6Carcinoma, Hepatocellular 6Pancreatic Neoplasms 5Colorectal Neoplasms 5Brain Neoplasms 5Oropharyngeal Neoplasms 4Lung Neoplasms 4Hypopharyngeal Neoplasms 4Head and Neck Neoplasms 4Glioma 4Recurrence 3Prostatic Neoplasms 3Parkinson Disease 4, Autosomal Dominant Lewy Body 3Neoplasm Metastasis 3Mouth Neoplasms 3Melanoma 3Colonic Neoplasms 3Astrocytoma 3Triple Negative Breast Neoplasms 2Thyroid Neoplasms 2Skin Neoplasms 2

Interventions

pembrolizumab 96Carboplatin 67Paclitaxel 56Cyclophosphamide 40Capecitabine 30Specimen Handling 28sacituzumab govitecan 25130-nm albumin-bound paclitaxel 24Gemcitabine 22Magnetic Resonance Spectroscopy 21Doxorubicin 20olaparib 19Taxes 19Biopsy 19Albumin-Bound Paclitaxel 19Drug Therapy 16atezolizumab 13Nivolumab 13toripalimab 12Radiotherapy 12Epirubicin 12durvalumab 11Docetaxel 10Cisplatin 10Bevacizumab 10eribulin 9fludarabine 8Standard of Care 7Radiation 7Injections 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Triple Negative Breast Neoplasms × Surgical Procedures, Operative × 1 year × Clear all
NCT04770272 2026-01-12

neoMono

Palleos Healthcare GmbH

Phase 2 Terminated
442 enrolled 42 charts
Breast

Triple Negative Breast Neoplasms

NCT07016399 2025-10-30

Neoadjuvant Darolutamide Alone or in Combination With Standard Therapy for Stage II-IIIA, AR+, TNBC

Vanderbilt-Ingram Cancer Center

Phase 2 Recruiting
51 enrolled
Breast

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡